Jan 4 (Reuters) - WuXi Biologics (Cayman) Inc:
* WUXI BIOLOGICS AND GSK ENTER INTO LICENSE AGREEMENT ON MULTIPLE NOVEL BI- & MULTI-SPECIFIC T CELL ENGAGERS
* WUXI BIOLOGICS - WILL RECEIVE AN UPFRONT PAYMENT OF $40 MILLION AND TIERED ROYALTIES ON NET SALES
* WUXI BIOLOGICS- WILL PROVIDE AN EXCLUSIVE LICENSE TO GSK FOR ONE PRECLINICAL BI-SPECIFIC ANTIBODY AND OPTION OF 3 ADDITIONAL BI-/MULTI-SPECIFIC TCE ANTIBODIES Source text for Eikon: Further company coverage: